Table 1.
Pre-intervention period n=300 a |
Intervention period n=200 a |
|
---|---|---|
Age, mean (standard deviation) | 52.8 (15.8) | 52.6 (17.8) |
Male | 171 (57) | 110 (55) |
Comorbidities | ||
Diabetes mellitus | 87 (29) | 66 (33) |
Antibiotic use within 6 months | 67 (22) | 57 (29) |
COPD | 48 (16) | 36 (18) |
Hospitalization within 90 days | 46 (15) | 33 (17) |
HIV infection | 17 (6) | 3 (2) |
Pregnancy | 13 (4) | 6 (3) |
Cirrhosis | 13 (4) | 11 (6) |
History of multi-drug resistant organism b | 12 (4) | 5 (3) |
End-stage renal disease | 9 (3) | 5 (3) |
Failed outpatient antibiotics c | 17 (6) | 7 (4) |
Hospital length of stay, median days (IQR) | 4 (3–5) | 4 (3–6) |
ICU admission | 53 (18) | 35 (18) |
Infectious Diseases consultation | 42 (14) | 29 (15) |
Indications for discharge antibiotics | ||
Urinary tract infection | 72 (24) | 42 (21) |
Community-acquired pneumonia | 52 (17) | 35 (18) |
Skin and soft tissue infection | 62 (21) | 34 (17) |
Gastrointestinal infection | 46 (15) | 22 (11) |
Osteoarticular infection | 22 (7) | 16 (8) |
COPD exacerbation d | 23 (8) | 36 (18) |
Head and neck infection | 15 (5) | 18 (9) |
Bacteremia | 15 (5) | 9 (5) |
Other | 40 (13) | 26 (13) |
≥2 indications for therapy | 37 (12) | 25 (13) |
No significant differences between pre-intervention and intervention cohort (p>0.05 for all subgroups) with the exception of COPD exacerbation
Defined as prior infection with methicillin-resistant Staphylococcus aureus, vancomycin resistant Enterococci, or extended spectrum beta-lactamase producing Enterobacteriaceae.
Defined as lack of clinical response to outpatient therapy requiring hospital admission.
COPD exacerbations significantly more frequent in intervention cohort (p=0.001) IQR, interquartile range; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus